(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Gastroenterology, Hepatology and Nutrition Fellowship program is a key part of the division's overall success. Our team of specialists boast a wide variety of backgrounds and areas of focus.
Learn more about our Clinical team. Learn more about our Research team.
Lee A. Denson, MD Medical Director, Inflammatory Bowel Disease Center 513-636-7575 firstname.lastname@example.org
Medical Director, Inflammatory Bowel Disease Center
Professor, UC Department of Pediatrics
Inflammatory bowel disease; growth failure; celiac disease
The primary focus of Dr. Lee A. Denson's laboratory is to determine the molecular basis for alterations in growth hormone signaling in inflammatory bowel diseases (IBD).
Normal growth and development are dependent upon the ability of growth hormone to regulate IGF-1 expression. Evidence from studies in children with IBD and mouse models of colitis indicates that inflammatory cytokines which are up regulated in this setting may cause an acquired GH resistance. Consequences may include growth failure, altered body composition and impaired mucosal healing.
We are using complementary experimental and patient-based approaches to investigate regulation of growth hormone signaling in mouse models of colitis and in children with Crohn's disease. These include down regulation of the growth hormone receptor and up regulation of a family of post-receptor inhibitory proteins, the Suppressors of Cytokine Signaling (SOCS). These studies should lead to the development of more effective therapies for children with IBD and other chronic inflammatory conditions.
MD: Medical College of Virginia, Richmond, VA, 1993.
Residency: Yale-New Haven Hospital, New Haven, CT, 1993-96.
Certification: Pediatrics, 1996 and 2002.
Fellowship: Yale University School of Medicine, New Haven, CT, 1996-99.
Herzer M, Denson LA, Baldassano RN, Hommel KA. Family functioning and health-related quality of life in adolescents with pediatric inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011 Jan;23(1):95-100.
Gray WN, Denson LA, Baldassano RN, Hommel KA. Disease activity, behavioral dysfunction, and health-related quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2010 Nov 4.
Lawal TA, Frischer JS, Falcone RA, Chatoorgoon K, Denson LA, Levitt MA. The transanal approach with laparoscopy or laparotomy for the treatment of rectal strictures in Crohn's disease. J Laparoendosc Adv Surg Tech A. 2010 Nov;20(9):791-5.
Denson LA, Kim MO, Bezold R, Carey R, Osuntokun B, Nylund C, Willson T, Bonkowski E, Li D, Ballard E, Collins M, Moyer MS, Klein DJ. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):130-9.
Nylund CM, Denson LA, Noel JM. Bacterial enteritis as a risk factor for childhood intussusception: a retrospective cohort study. J Pediatr. 2010 May;156(5):761-5.
Ingerski LM, Baldassano RN, Denson LA, Hommel KA. Barriers to oral medication adherence for adolescents with inflammatory bowel disease. J Pediatr Psychol. 2010 Jul;35(6):683-91.
Tomer G, Wetzler G, Keddache M, Denson LA. Polymorphisms in the IBD5 locus are associated with Crohn disease in pediatric Ashkenazi Jewish patients. J Pediatr Gastroenterol Nutr. 2009 May;48(5):531-7.
Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE, Stevens CA, Beck DC, Denson LA, Carey BC, Keicho N, Krischer JP, Yamada Y, Trapnell BC. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009 Mar 12;113(11):2547-56.
Han X, Uchida K, Jurickova I, Koch D, Willson T, Samson C, Bonkowski E, Trauernicht A, Kim MO, Tomer G, Dubinsky M, Plevy S, Kugathsan S, Trapnell BC, Denson LA. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology. 2009 Apr;136(4):1261-71, e1-3.
Denson LA. Growth hormone therapy in children and adolescents: pharmacokinetic/pharmacodynamic considerations and emerging indications. Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1569-80. Review.
Mike A. Leonis, MD, PhD 513-636-4415 email@example.com
Associate Professor, UC Department of Pediatrics
Pediatric hepatology, especially acute liver failure; inflammatory disease processes of the liver; hepatoblastoma; mechanisms of hepatic tumor formation
MD: Washington University School of Medicine, St. Louis, MO, 1996.
PhD: Washington University School of Medicine, St. Louis, MO, 1996.
Procter Scholar: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2002-2005.
Fellowship: Cincinnati Children's, Cincinnati, OH, 1999-2002.
Residency: Primary Children's Hospital Medical Center, University of Utah School of Medicine, Salt Lake City, UT, 1996-1999.
Certification: American Board of Pediatrics, 1999; Pediatric Gastroenterology, Hepatology and Nutrition, 2003.
Stuart WD, Kulkarni RM, Gray JK, Vasiliauskas J, Leonis MA, Waltz SE. Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice. Hepatology. 2011 May;53(5):1618-28.
Kenny AP, Crimmins NA, Mackay DJ, Hopkin RJ, Bove KE, Leonis MA. Concurrent course of transient neonatal diabetes with cholestasis and paucity of interlobular bile ducts: a case report. Pediatr Dev Pathol. 2009 Sep-Oct;12(5):417-20.
Leonis MA, Balistreri WF. Evaluation and management of end-stage liver disease in children. Gastroenterology. 2008 May;134(6):1741-51.
Caldwell CC, Martignoni A, Leonis MA, Ondiveeran HK, Fox-Robichaud AE, Waltz SE. Ron receptor tyrosine kinase-dependent hepatic neutrophil recruitment and survival benefit in a murine model of bacterial peritonitis. Crit Care Med. 2008 May;36(5):1585-93.
Leonis MA, Thobe MN, Waltz SE. Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol. 2007 Aug;3(4):441-8. Review.
Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 2006 Dec 15;66(24):11967-74.
Wetzel CC, Leonis MA, Dent A, Olson MA, Longmeier AM, Ney PA, Boivin GP, Kader SA, Caldwell CC, Degen SJ, Waltz SE. Short-form Ron receptor is required for normal IFN-gamma production in concanavalin A-induced acute liver injury. Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G253-61.
Leonis MA, Toney-Earley K, Degen SJ, Waltz SE. Deletion of the Ron receptor tyrosine kinase domain in mice provides protection from endotoxin-induced acute liver failure. Hepatology. 2002 Nov;36(5):1053-60.
Daniel Mallon, MD Pediatric Gastroenterologist, Division of Gastroenterology, Hepatology and Nutrition 513-636-4415 firstname.lastname@example.org
Pediatric Gastroenterologist, Division of Gastroenterology, Hepatology and Nutrition
Associate Program Director for Student and Resident Education, Division of Gastroenterology, Hepatology and Nutrition
Assistant Professor, UC Department of Pediatrics
Pediatric gastroenterology; inflammatory bowel disease; constipation; gastroesophageal reflux; celiac disease
MD: Indiana University School of Medicine, Indianapolis, IN, 2007.
Residency: Pediatrics, Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, 2007-2010.
Chief Resident: Pediatrics, Seattle Children's Hospital, Seattle, WA, 2010-2011.
Fellowship: Pediatric Gastroenterology, Boston Children's Hospital/Harvard Medical School, Boston, MA, 2011-2014.
Scott P. Pentiuk, MD Pediatric Gastroenterologist, Division of Gastroenterology, Hepatology and Nutrition 513-636-4415 email@example.com
Feeding disorders; medical education
MD: University of Cincinnati College of Medicine, Cincinnati, Ohio, 2002.
Residency: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2005.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2008.
Boamah LM, Bohren JR, Pentiuk S, Baker R, Yi M, Moyer MS. Development and testing of a CD-ROM program for improving adolescent knowledge of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2010 May;50(5):521-5.
Pentiuk S, Putnam PE, Collins MH, Rothenberg ME. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):152-60.
Pentiuk SP, Miller CK, Kaul A. Eosinophilic esophagitis in infants and toddlers. Dysphagia. 2007 Jan;22(1):44-8.
Stavra A. Xanthakos, MD, MS Director, Steatohepatitis Center 513-636-4415 firstname.lastname@example.org
Director, Steatohepatitis Center
Medical Director, Surgical Weight Loss Program for Teens
Associate Director, Gastroenterology Fellowship Program
Non-alcoholic fatty liver disease and steatohepatitis; pediatric obesity; bariatric surgery; nutrition
Stavra A. Xanthakos, MD, is an attending physician in the Division of Gastroenterology, Hepatology and Nutrition, the co-director of the Cincinnati Children’s Steatohepatitis Center, and the medical director of the Surgical Weight Loss Program for Teens. She is an assistant professor for the University of Cincinnati College of Medicine. She also partners with physicians and staff in Cincinnati Children’s Center for Better Health and Nutrition in the evaluation and management of pediatric patients suffering from severe pediatric obesity and related complications.
Dr. Xanthakos received her medical degree from Duke University in 1997 and a Master of Science degree in molecular epidemiology from the University of Cincinnati in 2006. Her post-doctoral training, including residency, chief residency and fellowship were completed at Cincinnati Children's and she joined the faculty within the University of Cincinnati College of Medicine in 2005. During her fellowship, Dr. Xanthakos investigated the prevalence and outcome of non-alcoholic fatty liver disease (NAFLD) in young adult women as her master’s thesis in molecular epidemiology. Her current clinical and translational research is focused on identify the predictors and outcome of obesity-related liver disease (nonalcoholic fatty liver disease and steatohepatitis), in obese adolescents undergoing bariatric surgery. She is also a co-investigator in the NIH sponsored Teen LABS, a multicenter consortium investigating bariatric surgery in adolescents and in the NIH-sponsored NASH Clinical Research Network. Additional research interests of Dr. Xanthakos include the treatment and prevention of pediatric obesity, outcomes of bariatric surgery in adolescents, malnutrition in pediatric obesity, as well as identifying genetic and environmental risk factors for pediatric nonalcoholic fatty liver disease to enable better evaluation and treatment options. She also leads clinical quality improvement initiatives in the Steatohepatitis Center, which are aligned with divisional and institutional initiatives to achieve measurable improvements in children’s health and disease outcomes.
Dr. Xanthakos has published extensively in the field of pediatric obesity, bariatric medicine and non-alcoholic fatty liver disease. She regularly is invited to speak about pediatric obesity evaluation and management, particularly bariatric medicine, and pediatric nonalcoholic fatty liver disease.
MD: Duke University, Durham, NC, 1997.
MS: Molecular Epidemiology, University of Cincinnati, 2006.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1997-2000.
Chief Residency: Cincinnati Children's, Cincinnati, OH, 2000-01.
Clinical Fellowship: Gastroenterology, Hepatology & Nutrition, Cincinnati Children's , Cincinnati, OH, 2001-2004.
Research Fellowship: Molecular Epidemiology in Children's Environmental Health, Masters of Science, 2002-2005.
Certification: Pediatrics, 2008; Pediatric Gastroenterology, 2005.
Carter-Kent C, Alkhouri N, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ and Feldstein AE. The relationship of steatosis grade, zone and type to key histological features in children with nonalcoholic fatty liver disease. Journal of Pediatric Gastroenterology, Hepatology and Nutrition. 2011;52(2):190-7.
Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010 Sep;52(3):934-44.
Kohli R, Boyd T, Lake K, Dietrich K, Nicholas L, Balistreri WF, Ebach D, Shashidhar H, Xanthakos SA. Rapid progression of NASH in childhood. J Pediatr Gastroenterol Nutr. 2010 Apr;50(4):453-6.
Xanthakos SA. Nutritional deficiencies in obesity and after bariatric surgery. Pediatr Clin North Am. 2009 Oct;56(5):1105-21.
Inge TH, Xanthakos S. Sleeve gastrectomy for childhood morbid obesity: why not? Obes Surg. 2010 Jan;20(1):118-20.
Inge TH, Jenkins TM, Zeller M, Dolan L, Daniels SR, Garcia VF, Brandt ML, Bean J, Gamm K, Xanthakos SA. Baseline BMI is a strong predictor of nadir BMI after adolescent gastric bypass. J Pediatr. 2010 Jan;156(1):103-108.
Xanthakos SA. Bariatric surgery for extreme adolescent obesity: Indications, outcomes, and physiologic effects on the gut-brain axis. Pathophysiology. 2008 Aug;15(2):135-46.
Roehrig HR, Xanthakos SA, Sweeney J, Zeller MH, Inge TH. Pregnancy after gastric bypass surgery in adolescents. Obes Surg. 2007 Jul;17(7):873-7.
Miller RJ, Xanthakos SA, Hillard PJ, Inge TH. Bariatric surgery and adolescent gynecology. Curr Opin Obstet Gynecol. 2007 Oct;19(5):427-33.
Inge TH, Xanthakos SA, Zeller MH. Bariatric surgery for pediatric extreme obesity: now or later? Int J Obes (Lond). 2007 Jan;31(1):1-14.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center